Trastuzumab emtansine
- Generic Name
- Trastuzumab emtansine
- Brand Names
- Kadcyla
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1018448-65-1
- Unique Ingredient Identifier
- SE2KH7T06F
- Background
Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-microtubule agent, DM1 (a maytansine deriva...
- Indication
Used in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment.
- Associated Conditions
- HER2-Positive Early Stage Breast Cancer, HER2-positive, Metastatic Breast Cancer
- Associated Therapies
- -
ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer
- First Posted Date
- 2018-07-16
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 82
- Registration Number
- NCT03587740
- Locations
- 🇺🇸
The Stamford Hospital, Stamford, Connecticut, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital, South Weymouth, Massachusetts, United States
T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer
- First Posted Date
- 2018-05-21
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- University of Arizona
- Target Recruit Count
- 55
- Registration Number
- NCT03530696
- Locations
- 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸JPS Health Network, Fort Worth, Texas, United States
A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer
- First Posted Date
- 2018-02-12
- Last Posted Date
- 2021-01-15
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Target Recruit Count
- 6
- Registration Number
- NCT03429101
- Locations
- 🇺🇸
Pacific Cancer Medical Center, Inc., Anaheim, California, United States
🇺🇸Los Angeles Hematology Oncology Medical Group, Glendale, California, United States
Study of Trastuzumab-emtansine in Patients With HER2-positive Metastatic Colorectal Cancer Progressing After Trastuzumab and Lapatinib.
- First Posted Date
- 2018-02-01
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- Fondazione del Piemonte per l'Oncologia
- Target Recruit Count
- 13
- Registration Number
- NCT03418558
- Locations
- 🇮🇹
Fondazione del Piemonte per l'Oncologia, Candiolo, Italy
🇮🇹Grande Ospedale Metropolitano Niguarda, Milano, Italy
🇮🇹IOV - Istituto Oncologico Veneto, Padova, Italy
4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer
- First Posted Date
- 2017-12-06
- Last Posted Date
- 2022-10-19
- Lead Sponsor
- George W. Sledge Jr.
- Target Recruit Count
- 18
- Registration Number
- NCT03364348
- Locations
- 🇺🇸
Stanford University, School of Medicine, Palo Alto, California, United States
T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery
- Conditions
- Interventions
- First Posted Date
- 2017-06-19
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 12
- Registration Number
- NCT03190967
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Study of the Pharmacokinetics and Safety of Trastuzumab Emtansine in Chinese Participants With Locally Advanced Inoperable or Metastatic HER2+ Breast Cancer
- First Posted Date
- 2017-05-15
- Last Posted Date
- 2018-11-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 11
- Registration Number
- NCT03153163
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center; Medical Oncology, Shanghai, China
A Study Of Pembrolizumab In Combination With Trastuzumab-DM1
- First Posted Date
- 2017-01-26
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT03032107
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2016-12-21
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 20
- Registration Number
- NCT02999672
- Locations
- 🇪🇸
Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain
🇮🇹IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica, Meldola, Emilia-Romagna, Italy
🇸🇰Narodny onkologicky ustav, Bratislava, Slovakia
A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy
- Conditions
- Interventions
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2021-02-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 202
- Registration Number
- NCT02924883
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
🇩🇪Nationales Centrum für Tumorerkrankungen (NCT) ; Gyn. Onk. Frauenklinik; Uniklinikum Heidelberg, Heidelberg, Germany
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.